论文部分内容阅读
目的评价人源化抗Her2单抗(MIL41)注射液体内外对人乳腺癌细胞BT474的抗癌效应。方法流式细胞仪分析人乳腺癌BT474细胞的Her2表达量;采用CCK-8法测定MIL41体外对BT474细胞的增殖抑制效应;用裸鼠皮下移植瘤模型法,评价MIL41的体内抗癌作用。结果流式细胞仪显示BT474细胞为Her2高表达的细胞系;体外实验显示,MIL41对受试细胞的增殖具有良好的抑制作用;体内实验表明,MIL41对裸鼠皮下移植瘤生长具有较强的抑制作用,呈现良好的量效关系,在给药剂量为12mg·kg-1时,瘤重抑制率达到56.3%(P<0.05)。结论人源化抗Her2单抗体内外对人乳腺癌细胞BT474具有良好的抑制作用。
Objective To evaluate the anticancer effect of humanized anti-Her2 mAb (MIL41) injection on human breast cancer cell line BT474 both in vitro and in vivo. Methods Her2 expression in human breast cancer BT474 cells was analyzed by flow cytometry. The inhibitory effect of MIL41 on the proliferation of BT474 cells in vitro was evaluated by CCK-8 assay. The anti-tumor effect of MIL41 in vivo was evaluated by subcutaneous xenograft tumor model in nude mice. Results Flow cytometry showed that BT474 cells were Her2-overexpressing cell lines. In vitro experiments showed that MIL41 had a good inhibitory effect on the proliferation of test cells. In vivo experiments showed that MIL41 had a strong inhibitory effect on the growth of subcutaneous xenografts in nude mice (P <0.05). The inhibition rate of tumor weight reached 56.3% at the dosage of 12 mg · kg-1. Conclusion Humanized anti-Her2 monoclonal antibody has a good inhibitory effect on human breast cancer cell line BT474 both in vitro and in vivo.